Oligosaccharides

Inbiose applies for FDA GRAS approval of four new Human Milk Oligosaccharides

Retrieved on: 
Tuesday, July 6, 2021
Breastfeeding, Branches of biology, Nutrition, Food and drink, Carbohydrate chemistry, Chemistry, Dairy products, Oligosaccharides, Human milk oligosaccharide, Milk, Breast milk, Infant formula

Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.

Key Points: 
  • Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.
  • Inbiose has been developing a wide range of human-identical milk oligosaccharides that can be industrially produced by sustainable fermentation processes.
  • Inbiose is currently developing its next generation HMOs that will permit infant formula to better replicate the composition of breast milk.
  • Inbiose is a Belgium-based biotech company focused on the research, development and commercialization of specialty carbohydrates, including human milk oligosaccharides.

Inbiose applies for FDA GRAS approval of four new Human Milk Oligosaccharides

Retrieved on: 
Tuesday, July 6, 2021
Breastfeeding, Branches of biology, Nutrition, Food and drink, Carbohydrate chemistry, Chemistry, Dairy products, Oligosaccharides, Human milk oligosaccharide, Milk, Breast milk, Infant formula

Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.

Key Points: 
  • Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.
  • Inbiose has been developing a wide range of human-identical milk oligosaccharides that can be industrially produced by sustainable fermentation processes.
  • Inbiose is currently developing its next generation HMOs that will permit infant formula to better replicate the composition of breast milk.
  • Inbiose is a Belgium-based biotech company focused on the research, development and commercialization of specialty carbohydrates, including human milk oligosaccharides.

Global Galacto-oligosaccharide (GOS) Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021
Alternative medicine, Fitness & Nutrition, Health, Other Health, Galactooligosaccharide, Oligosaccharides, Compound annual growth rate

The "Galacto-oligosaccharide (GOS) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Galacto-oligosaccharide (GOS) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Food & Beverage, one of the segments analyzed in the report, is projected to record a 8.4% CAGR and reach US$1.4 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $238 Million, While China is Forecast to Grow at 12.6% CAGR
    The Galacto-oligosaccharide (GOS) market in the U.S. is estimated at US$238 Million in the year 2020.
  • In the global Other Applications segment, USA, Canada, Japan, China and Europe will drive the 5.8% CAGR estimated for this segment.

Global Human Milk Oligosaccharides (HMO) Markets, 2016-2019 & 2020-2026 - Rise in Health Awareness Among People and the Popularity of Artificial Synthesis Methods - ResearchAndMarkets.com

Retrieved on: 
Friday, January 8, 2021
Health, General Health, Breastfeeding, Branches of biology, Food and drink, Carbohydrates, Nutrition, Carbohydrate chemistry, Oligosaccharides, Dairy products, Human milk oligosaccharide, Milk, Breast milk, Infant formula

HMOs (Human Milk Oligosaccharides) are sugars present in human breast milk and are the third-most-abundant solid component (after lactose and fats).

Key Points: 
  • HMOs (Human Milk Oligosaccharides) are sugars present in human breast milk and are the third-most-abundant solid component (after lactose and fats).
  • The growth of the Human Milk Oligosaccharides industry is accentuated by a variety of factors.
  • Human Milk Oligosaccharides (HMOs) have recently been used as an essential component of food supplements and infant formulas.
  • Infant formulas, developed from bovine milk, contain less concentration of oligosaccharides compared to human milk.

The Global Galacto-oligosaccharide Market is expected to grow by $ 486.79 mn during 2020-2024, progressing at a CAGR of 10% during the forecast period

Retrieved on: 
Wednesday, October 14, 2020
Oligosaccharides, Galactooligosaccharide, Trend

The analyst has been monitoring the galacto-oligosaccharide market and it is poised to grow by $ 486.79 mn during 2020-2024, progressing at a CAGR of 10% during the forecast period.

Key Points: 
  • The analyst has been monitoring the galacto-oligosaccharide market and it is poised to grow by $ 486.79 mn during 2020-2024, progressing at a CAGR of 10% during the forecast period.
  • Our reports on galacto-oligosaccharide market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • The market is driven by the health benefits of galacto-oligosaccharides and growing popularity of e-commerce in healthcare industry.

Sugarlogix Welcomes Paula Hicks as new Chief Technology Officer

Retrieved on: 
Wednesday, September 30, 2020
Chemistry, Physical sciences, Natural sciences, Carbohydrate chemistry, Nutrition, Oligosaccharides, Breastfeeding, Human milk oligosaccharide, Microbiology, Vanillin, Hicks, Cision

OAKLAND, Calif., Sept. 30, 2020 /PRNewswire-PRWeb/ -- Sugarlogix , a bioengineering company creating functional oligosaccharides with health benefits, today announced the appointment of Paula Hicks as its new Chief Technology Officer (CTO).

Key Points: 
  • OAKLAND, Calif., Sept. 30, 2020 /PRNewswire-PRWeb/ -- Sugarlogix , a bioengineering company creating functional oligosaccharides with health benefits, today announced the appointment of Paula Hicks as its new Chief Technology Officer (CTO).
  • Before joining Sugarlogix, Hicks was at Evolva for more than seven years, most recently as the Senior Vice President of Technology in the Commercial Team.
  • While at Evolva, Hicks had vital leadership roles in commercializing products such as stevia, vanillin, and nootkatone.
  • "Sugarlogix's novel technology to utilizing yeast to produce HMOs (human milk oligosaccharides) and the technology's relative maturity immediately impressed me," said Hicks.

Galacto-oligosaccharide Market: COVID-19 Business Continuity Plan | Evolving Opportunities with Clasado Biosciences and Fonterra Co operative Group Ltd. | Technavio

Retrieved on: 
Thursday, September 17, 2020
Alternative medicine, Health, Fitness & Nutrition, Dairy farming in New Zealand, Oligosaccharides, Chinese milk scandal, Fonterra, Prebiotic, Galactooligosaccharide, Food and drink, Biotic, Companies, Branches of biology

In addition, the use of nutraceuticals and prebiotics in treating chronic diseases is anticipated to boost the growth of the galacto-oligosaccharide market.

Key Points: 
  • In addition, the use of nutraceuticals and prebiotics in treating chronic diseases is anticipated to boost the growth of the galacto-oligosaccharide market.
  • They stimulate the activity of gut bacteria, which improves immunity, enhance the absorption of essential nutrients, and produce powerful antioxidant H2 gas.
  • Fonterra Co operative Group Ltd.
    Fonterra Co operative Group Ltd. operates its business through segments such as Ingredients, Consumer and foodservice, and China Farms.
  • New Francisco (Yunfu City) Biotechnology Corp. Ltd.
    New Francisco (Yunfu City) Biotechnology Corp. Ltd. operates its business through a unified segment.

N-Glycan Characterization via LC-MS, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, September 3, 2020
Chemistry, Physical sciences, Natural sciences, Carbohydrates, Glycomics, Biochemistry, Laboratory techniques, Glycan, Oligosaccharides, Assay

Therefore, a highly sensitive assay that can identify and quantify glycan species below 0.1 percent relative abundance is essential.

Key Points: 
  • Therefore, a highly sensitive assay that can identify and quantify glycan species below 0.1 percent relative abundance is essential.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.
  • Xtalks helps Life Science professionals stay current with industry developments, trends and regulations.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Jennewein Publishes New Results on the Norovirus-inhibiting Effect of Complex Oligosaccharides

Retrieved on: 
Wednesday, May 27, 2020
Branches of biology, Medical specialties, Breastfeeding, Health, Oligosaccharides, Carbohydrate chemistry, Human milk oligosaccharide, Microbiology, Nutrition, Norovirus, Breast milk

Breast-fed infants are less likely than bottle-fed infants to contract norovirus infections, and earlier work has indicated a link between this protective effect and human milk oligosaccharides (HMOs).

Key Points: 
  • Breast-fed infants are less likely than bottle-fed infants to contract norovirus infections, and earlier work has indicated a link between this protective effect and human milk oligosaccharides (HMOs).
  • In this latest study, entitled "Biotechnologically produced fucosylated oligosaccharides inhibit the binding of human noroviruses to their natural receptors", we extended our work to include additional HMOs such as lacto-N-fucopenatose I and even more complex oligosaccharides.
  • But the development of more complex oligosaccharides, which mimic the virus receptors even more closely, allows us to significantly improve this protective effect."
  • In 2015, the US Food and Drug Administration (FDA) granted Jennewein Biotechnologie a license to market 2-FL in the USA.

Jennewein Publishes New Results on the Norovirus-inhibiting Effect of Complex Oligosaccharides

Retrieved on: 
Wednesday, May 27, 2020
Branches of biology, Medical specialties, Breastfeeding, Health, Oligosaccharides, Carbohydrate chemistry, Human milk oligosaccharide, Microbiology, Nutrition, Norovirus, Breast milk

Breast-fed infants are less likely than bottle-fed infants to contract norovirus infections, and earlier work has indicated a link between this protective effect and human milk oligosaccharides (HMOs).

Key Points: 
  • Breast-fed infants are less likely than bottle-fed infants to contract norovirus infections, and earlier work has indicated a link between this protective effect and human milk oligosaccharides (HMOs).
  • In this latest study, entitled "Biotechnologically produced fucosylated oligosaccharides inhibit the binding of human noroviruses to their natural receptors", we extended our work to include additional HMOs such as lacto-N-fucopenatose I and even more complex oligosaccharides.
  • But the development of more complex oligosaccharides, which mimic the virus receptors even more closely, allows us to significantly improve this protective effect."
  • In 2015, the US Food and Drug Administration (FDA) granted Jennewein Biotechnologie a license to market 2-FL in the USA.